MIG AG has invested EUR 27m in Antisense Pharma GmbH, a developer of targeted therapies for malignant tumors.
Shares are sold by shares were held by CapMan Buyout X Fund A and CapMan Buyout X Fund B
Advent made a takeover offer of 165 pence per share in cash, which represents a 34% premium in July
Business strategy platform will expand its product and triple its team size
Fund targets companies operating in the healthcare industry, primarily pharma, medtech and outsourced services